Lista de obras - Pietro Lampertico - Dominio Público Uruguay

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

scientific article published on 02 July 2018

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

artículo científico publicado en 2018

A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis.

artículo científico publicado en 2003

Acute hepatitis following assumption of a herbal remedy

scientific article published on 01 April 2008

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D

scientific article published on 11 December 2018

Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.

artículo científico publicado en 2005

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

artículo científico publicado en 2005

Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.

artículo científico publicado en 2012

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

artículo científico

Antiviral drugs for HBV liver disease.

artículo científico publicado en 2011

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

artículo científico publicado en 2012

Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells

artículo científico publicado en 2004

Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients

artículo científico publicado en 2020

Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B

artículo científico publicado en 2018

Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B

artículo científico publicado en 2020

Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19

artículo científico publicado en 2020

Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C.

artículo científico publicado en 2013

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

artículo científico publicado en 2020

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

artículo científico publicado en 2020

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage

artículo científico publicado en 2007

Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature

artículo científico

Detection of the hepatitis B virus major pre-core mutation by the amplification refractory mutation system technique

artículo científico publicado en 1993

Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method

scientific article published on 01 July 1993

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

artículo científico publicado en 2011

Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation

artículo científico publicado en 2011

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals

artículo científico publicado en 2017

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

scientific article published on 07 January 2019

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey

scientific article published on 22 May 2019

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

scientific article published on 26 October 2011

Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B

scientific article published on 10 July 2006

Epidemiology and surveillance for hepatocellular carcinoma: New trends

scientific article published on 01 February 2020

Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C

artículo científico publicado en 2010

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.

artículo científico publicado en 2015

Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.

artículo científico publicado en 2015

Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

artículo científico publicado en 2008

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B

artículo científico publicado en 2019

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts

artículo científico publicado en 2020

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

artículo científico publicado en 2012

HBV and HCV therapy.

artículo científico publicado en 2009

HBV-related liver disease in renal insufficiency: successful antiviral therapy with entecavir

artículo científico publicado en 2011

HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

artículo científico publicado en 2014

Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs

artículo científico publicado en 2020

Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).

artículo científico publicado en 2017

Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon

artículo científico publicado en 1995

Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?

scientific article published on 01 February 2013

Hepatitis D - how is the fight against this foe going?

artículo científico publicado en 2019

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

artículo científico publicado en 2018

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study

artículo científico publicado en 2019

High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity

artículo científico publicado en 2001

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

scientific article published on 11 December 2020

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

artículo científico publicado en 2020

IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients

artículo científico publicado en 2017

IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection

artículo científico publicado en 2012

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

artículo científico publicado en 2012

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

scientific article published on 27 April 2010

Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma.

artículo científico publicado en 2007

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.

artículo científico publicado en 2016

Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues

scientific article published on 07 November 2019

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1

scientific article published on 14 March 2019

Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.

artículo científico publicado en 2015

Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B.

artículo científico publicado en 2018

Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply.

artículo científico publicado en 2014

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?

artículo científico publicado en 2014

Letter: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients - authors' reply

artículo científico publicado en 2016

Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

artículo científico publicado en 2011

Long-term evolution of anti-HCV-positive renal transplant recipients

artículo científico publicado en 1998

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

artículo científico publicado en 2003

Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study

artículo científico publicado en 2016

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

artículo científico publicado en 2007

Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.

artículo científico publicado en 2014

Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy

scientific article published on 12 August 2019

Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion

artículo científico publicado en 1993

Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations

artículo científico publicado en 2018

Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients.

artículo científico publicado en 2007

Natural history of hepatitis C virus infection in adult renal graft recipients

artículo científico publicado en 2005

Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.

artículo científico publicado en 2015

Non-invasive assessment of liver fibrosis in chronic hepatitis B.

artículo científico publicado en 2014

Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimization

scientific article published on 19 September 2013

Optimal management of hepatitis B virus infection - EASL Special Conference

artículo científico

Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?

artículo científico

Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?

artículo científico publicado en 2014

Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go.

artículo científico publicado en 2013

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

artículo científico publicado en 2015

Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice

artículo científico publicado en 2009

Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.

artículo científico publicado en 2013

PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.

artículo científico publicado en 2013

Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.

artículo científico publicado en 2013

Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression

artículo científico publicado en 2018

Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients.

artículo científico publicado en 2015

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

scientific article published on 30 August 2019

Prophylaxis and treatment of hepatitis B in immunocompromised patients

artículo científico publicado en 2007

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.

artículo científico publicado en 2005

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

artículo científico publicado en 2012

Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders

artículo científico publicado en 2016

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

scientific article published on 04 August 2020

Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?

scientific article published on 14 June 2019

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

artículo científico publicado en 2012

Results of treatment of chronic hepatitis B with pegylated interferon.

artículo científico publicado en 2013

Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.

artículo científico publicado en 2016

Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection

artículo científico publicado en 2016

Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

artículo científico publicado en 2015

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

artículo científico publicado en 2016

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

scientific article published on 07 December 2018

Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers

artículo científico publicado en 1989

Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?

artículo científico publicado en 2014

TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals

scientific article published on 30 June 2019

Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B.

artículo científico publicado en 2017

Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.

artículo científico publicado en 2014

The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent

artículo científico publicado en 2014

The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma.

artículo científico publicado en 2003

The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV Caucasian cirrhotics on long-term oral therapy

scientific article published on 16 April 2020

The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.

artículo científico publicado en 2011

The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis

artículo científico publicado en 2014

The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study

artículo científico publicado en 2015

The prognosis and management of inactive HBV carriers.

artículo científico

The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy

scientific article published on 18 March 2015

The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients.

artículo científico publicado en 2013

The use of molecular assays in the management of viral hepatitis

artículo científico publicado en 2008

Tratamiento del virus de la hepatitis B: Cuáles pacientes deberían ser tratados con los análogos de nucleós(t)idos

artículo científico publicado en 2013

Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.

artículo científico publicado en 2011

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.

scientific article published on 26 January 2011

Treatment of hepatitis B: Is there still a role for interferon?

artículo científico publicado en 2018

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study

scientific article published on 25 June 2020

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

article published in 2012

Lista de obras de Pietro Lampertico

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis.

Acute hepatitis following assumption of a herbal remedy

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D

Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

Antiviral drugs for HBV liver disease.

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells

Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients

Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B

Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B

Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19

Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C.

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage

Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature

Detection of the hepatitis B virus major pre-core mutation by the amplification refractory mutation system technique

Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B

Epidemiology and surveillance for hepatocellular carcinoma: New trends

Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.

Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.

Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

HBV and HCV therapy.

HBV-related liver disease in renal insufficiency: successful antiviral therapy with entecavir

HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs

Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).

Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon

Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?

Hepatitis D - how is the fight against this foe going?

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study

High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients

IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma.

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.

Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1

Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.

Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B.

Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply.

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?

Letter: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients - authors' reply

Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

Long-term evolution of anti-HCV-positive renal transplant recipients

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.

Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy

Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion

Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations

Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients.

Natural history of hepatitis C virus infection in adult renal graft recipients

Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.

Non-invasive assessment of liver fibrosis in chronic hepatitis B.

Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimization